Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Oncolytics Biotech (ONCY – Research Report). The ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...